Genzyme Delivers Strong Fourth Quarter to Conclude Outsta... ( Reaffirms Outlook ...)

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

Date:2/13/2008

Reaffirms Outlook for Continued Growth

CAMBRIDGE, Mass., Feb. 13 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported financial results for the full year and fourth quarter of 2007 and provided an outlook for continued strong growth in 2008 and beyond.

Full-Year 2007

-- Total revenue in 2007 increased 20 percent to $3.8 billion from $3.2

billion in 2006. The increase was broadly driven by growth across all

segments of the company.

-- GAAP net income was $480.2 million, or $1.74 per diluted share,

compared with a net loss of $16.8 million, or $0.06 per diluted share,

for the previous year.

-- Non-GAAP net income increased 27 percent to $939.9 million, compared

with $742.7 million in 2006.

-- Non-GAAP earnings increased 25 percent to $3.47 per diluted share from

$2.77, exceeding the increased guidance of $3.35-$3.40 that Genzyme

provided in July.

-- The company generated approximately $1 billion in cash from operations

and increased its ending cash position to $1.5 billion while completing

two acquisitions, expanding its manufacturing infrastructure, and

repurchasing approximately 3.5 million shares under a three-year

program to reduce the dilutive effect of equity compensation.

-- Genzyme also continued to make excellent progress in building its

business to drive future growth. The company:

-- Expanded its emerging oncology franchise by securing worldwide

rights to its leukemia drug Clolar(R) (clofarabine) through the

acquisition of Bioenvision Inc.

-- Obtained marketing approval for four
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients

Post Your Comments:

Genzyme Delivers Strong Fourth Quarter to Conclude Outsta...( Reaffirms Outlook ...),Health